Page 92 - Haematologica August 2018

D. Salvatore et al.
7. Aversa F. Haploidentical haematopoietic
stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008;41(5):473-481.
8. Raiola AM , Dominietto A , di Grazia C, et al. Unmanipulated haploidentical trans- plants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20 (10):1573-1579.
9. Ciceri F, Labopin M, Aversa F, et al. A sur- vey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remis- sion at transplantation. Blood. 2008; 112(9):3574-3581.
10. Mancusi A, Ruggeri L, Velardi A. Haploidentical hematopoietic transplanta- tion for the cure of leukemia: from its biol- ogy to clinical translation. Blood. 2016; 128(23):2616-2623.
11. Mehta J, Singhal S, Gee AP, et al. Bone mar- row transplantation from partially HLA- mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant. 2004; 33(4):389–396.
12. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow trans- plantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophos- phamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
13. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/hap- loidentical blood and marrow transplanta- tion can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065-3073.
14. Ciurea SO, Zhang MJ, Bacigalupo A, et al. Haploidentical transplant with posttrans- plant cyclophosphamide vs matched unre- lated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
15. Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplanta- tion continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811-817.
16. Piemontese S, Ciceri F, Labopin M , et al. A comparison between allogeneic stem cell transplantation from unmanipulated hap- loidentical and unrelated donors in acute leukemia. J Hematol Oncol. 2017;10(1):24.
17. Bashey A, Zhang X, Jackson K, et al. Comparison of outcomes of hematopoietic cell transplants from T-replete haploidenti-
cal donors using post-transplantation Cyclophosphamide with 10 of 10 HLA-A, - B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant. 2016;22(1):125-133.
18. Di Stasi A, Milton DR, Poon LM, et al. Similar transplant outcomes for AML/MDS patients with haploidentical versus 10/10 HLA matched unrelated and related donors. Biol Blood Marrow Transplant. 2014;20(12):1975–1981.
19. Wang Y, Liu Q, Xu L, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956-3962.
20. Yoon JH, Kim HJ, Park SS, et al. Long term clinical outcomes of hematopoietic cell transplantation for intermediate to poor risk acute myeloid leukemia during first remission according to available donor types. Oncotarget. 2017;8(25):41590- 41604.
21. Grimwade D, Hills RK, Moorman V, et al. Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood. 2010;116(3):354-365.
22. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628- 1633.
23. Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free sur- vival for registry-based studies: an ALWP– EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-611.
24. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on AGvHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
25. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant. 2003;9(4):215-233.
26. Kaplan EL, Mayer P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 2008;53(282):457-481.
27. Fine JP, Gray RJ. A Proportional hazards model for the subdistribution of a compet- ing risk. J Am Stat Assoc. 2009; 446(94):496-509.
28. Ho D, Imai K, King G, et al. Matching as non-parametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15(3):199-236.
29. Ho ED, Imai K, King G, Stuart EA. MatchIt:
Nonparametric Preprocessing for Parametric Causal Inference. J Stat Softw. 2011;42(8):1-28.
30. Ringdén O, Karlsson H, Olsson R, et al. The allogeneic graft-versus-cancer effect. Br J Haematol. 2009;147(5):614-633.
31. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus- host disease: contribution to improved sur- vival afterallogeneic marrow transplanta- tion. N Engl J Med. 1981;304(25):1529- 1533.
32. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated risk adapted approach. Nat Rev Clin Oncol. 2012; 9(10):579-590.
33. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone mar- row transplantation: an association with acute graft-versus-host disease. Blood. 1986;67(4):1162-1167.
34. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78-83.
35. Abdul Wahid SF, Ismail NA, Mohd-Idris MR, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid Leukemia and acute lymphoblas- tic Leukemia: a meta-analysis. Stem Cells Dev. 2014; 23(21):2535-2352.
36. Nannya Y, Kataoka K, Hangaishi A, et al. The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transpl Int. 2011; 24(5):469-476.
37. Ringdén O, Labopin M, Ciceri F, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical sibling? Leukemia. 2016;30(2):447-455.
38. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical trans- plants in leukemia. Blood. 1991;78(8):2120- 2130.
39. Ringden O, Horowitz MM, Sondel P, et al. Methotrexate, cyclosporine, or both to pre- vent graft-versus-host disease after HLA- identical sibling bone marrow transplants for early leukemia? Blood. 1993;81(4):1094- 1101.
40. Yanada M, Emi N, Naoe T, et al. Allogeneic myeloablative transplantation for patients aged 50 years and over. Bone Marrow Transplant. 2004;34(1):29-35.
1328
haematologica | 2018; 103(8)